Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases
September 07, 2023 03:00 ET
|
Jeito Capital
Jeito Capital co-leads EUR 65 million (USD 711M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases Jeito Capital...
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
April 13, 2023 01:15 ET
|
Jeito Capital
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in...
Jeito Capital dirige un financement de série C de 96 millions d’euros (105 millions de dollars) dans Alentis Therapeutics pour développer les traitements innovants ciblant la Claudin-1 dans les maladies fibrotiques et certains cancers
April 13, 2023 01:15 ET
|
Jeito Capital
Jeito Capital dirige un financement de série C de 96 millions d’euros (105 millions de dollars) dans Alentis Therapeutics pour développer...
Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma pour Noema Pharma, une biopharma ciblant les maladies graves du système nerveux central
March 07, 2023 04:00 ET
|
Jeito Capital
Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma ciblant les maladies graves du système...
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders
March 07, 2023 04:00 ET
|
Jeito Capital
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central...
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars
December 06, 2022 07:00 ET
|
Jeito Capital
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars Ce nouveau tour de table permettra d’accélérer le développement clinique et...
Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing
December 06, 2022 07:00 ET
|
Jeito Capital
Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing The Series C extension round will...
Jeito Capital affirme son leadership dans le secteur biopharmaceutique européen avec la cession de Neogene Therapeutics à AstraZeneca
November 29, 2022 02:22 ET
|
Jeito Capital
Jeito Capital affirme son leadership dans le secteur biopharmaceutique européen avec la cession de Neogene Therapeutics à AstraZeneca ...
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics
November 29, 2022 02:19 ET
|
Jeito Capital
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics Deal...
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
November 22, 2022 05:00 ET
|
Jeito Capital
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients...